Action PMGC - ELAB

Votre Hub pour des idées et discussions en direct en temps réel

Premium

Dernier

1,25

Prix Achat

1,25

Prix Vente

1,26

Volume échangé

262 087

1,53 Fourchette du Jour 1,67

1,09 Plage de 52 semaines 165,96

Cap du marché

3,838M

Clôture Veille

1,65

Ouverture

1,63

Dernière Transaction

1.26

Dernière heure de transaction

Volume financier

US$ 415 651

VWAP

1,5859

Volume moyen (3 m)

2 421 577

Actions en circulation

3 070 000

Rendement du Dividende

Ratio Cours sur Bénéfices

-1,12

Bénéfice par action (BPA)

-1,4

Chiffre d'affairess

1,71M

Bénéfice net

-4,3M

Elevai Labs, Inc., a skincare development company, designs, manufactures, and markets skincare products. Its products include Empower and Enfinity post-skincare procedure care serums for the face, neck, and upper chest regions. The company was formerly known as Reactive Medical Labs Inc. and changed... Elevai Labs, Inc., a skincare development company, designs, manufactures, and markets skincare products. Its products include Empower and Enfinity post-skincare procedure care serums for the face, neck, and upper chest regions. The company was formerly known as Reactive Medical Labs Inc. and changed its name to Elevai Labs, Inc. in December 2021. Elevai Labs, Inc. was incorporated in 2020 and is based in Newport Beach, California. Show more

Secteur

Pharmaceutical Preparations

Industrie

Pharmaceutical Preparations

Siège social

Wilmington, Delaware, USA

Fondé

PMGC Holdings Inc est coté dans le secteur Pharmaceutical Preparations de la NASDAQ avec le ticker ELAB. Le dernier cours de clôture d'PMGC était de US$1,65. Au cours de la dernière année, les actions de PMGC ont été négociées dans une fourchette de prix de US$ 1,09 à US$ 165,96.

PMGC compte actuellement 3 070 000 actions en circulation. La capitalisation boursière d'PMGC est de US$5,07 million. PMGC a un ratio cours/bénéfice (ratio PE) de -1.12.

Form PRE 14A - Other preliminary proxy statements

Form 8-K - Current report

Northstrive Biosciences Inc., a Subsidiary of PMGC Holdings Inc., Announces Successful Submission of Pre-IND Meeting Request to FDA for EL-22, a Potential Breakthrough Obesity Therapy Targeting Fat Loss and Muscle Preservation in Combination with GLP-1 Rec

Northstrive Biosciences Inc. (“Northstrive Biosciences”) has submitted a pre-Investigational New Drug...

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form EFFECT - Notice of Effectiveness

Form 8-K - Current report

Northstrive Biosciences, Inc., a Subsidiary of PMGC Holdings Inc., Reports Positive Updates for Obesity Drug Candidates Targeting Fat Loss and Muscle Preservation used in Combination with GLP-1

Lead asset EL-22 is leveraging a myostatin-engineered probiotic approach to address obesity’s pressing issue of...

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors

PMGC Capital LLC, a subsidiary of PMGC Holdings Inc., Begins to Build Portfolio with Strategic Acquisition of shares in U.S.-Focused Uranium Energy and Fire Prevention Technology Companies

NEWPORT BEACH, Calif., Jan. 31, 2025 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (the “Company” or “PMGC”...

Northstrive Biosciences Inc., a Subsidiary of PMGC Holdings Inc., Signs Agreement For Preclinical Mouse Study of EL-32, a Potential Breakthrough Obesity Therapy Targeting Fat Loss and Muscle Preservation in Combination with GLP-1

Groundbreaking research to evaluate the effects of EL-32, alone and in combination with semaglutide, on...

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	-0.47	-27.3255813953	1.72	1.75	1.09	275489	1.66044086	CS
4	-0.73	-36.8686868687	1.98	2.1	1.09	736438	1.82159592	CS
12	-0.75	-37.5	2	4.05	1.09	2421577	2.71894311	CS
26	-73.53	-98.3284300615	74.78	78	1.09	69402268	7.82363128	CS
52	-136.69	-99.0938089024	137.94	165.96	1.09	34352724	8.26724543	CS
156	-798.75	-99.84375	800	848.84	1.09	27617703	10.935694	CS
260	-798.75	-99.84375	800	848.84	1.09	27617703	10.935694	CS

ELAB - Frequently Asked Questions (FAQ)

What is the current PMGC share price?

The current share price of PMGC is US$ 1,25

How many PMGC shares are in issue?

PMGC has 3 070 000 shares in issue

What is the market cap of PMGC?

The market capitalisation of PMGC is USD 5,07M

What is the 1 year trading range for PMGC share price?

PMGC has traded in the range of US$ 1,09 to US$ 165,96 during the past year

What is the PE ratio of PMGC?

The price to earnings ratio of PMGC is -1,12

What is the cash to sales ratio of PMGC?

The cash to sales ratio of PMGC is 2,82

What is the reporting currency for PMGC?

PMGC reports financial results in USD

What is the latest annual turnover for PMGC?

The latest annual turnover of PMGC is USD 1,71M

What is the latest annual profit for PMGC?

The latest annual profit of PMGC is USD -4,3M

What is the registered address of PMGC?

The registered address for PMGC is 251 LITTLE FALLS DRIVE, NEW CASTLE, WILMINGTON, DELAWARE, 19808

Which industry sector does PMGC operate in?

PMGC operates in the PHARMACEUTICAL PREPARATIONS sector

Volume
% Gagnants
% Perdants

Symbole	Prix	Vol.
SXTCChina SXT Pharmaceuticals Inc	US$ 0,84 (145,54%)	29,14M
STECSantech Holdings Limited	US$ 1,575 (142,20%)	121,33M
YYAIConnexa Sports Technologies Inc	US$ 1,245 (94,50%)	150,24M
ATPCAgape ATP Corporation	US$ 1,60 (70,94%)	75,86M
PEPGPepGen Inc	US$ 2,2868 (66,92%)	108,17M
THTarget Hospitality Corporation	US$ 5,10 (-45,51%)	13,06M
ICCTiCoreConnect Inc	US$ 1,33 (-35,12%)	289,74k
STAIScanTech AI Systems Inc	US$ 2,1401 (-34,95%)	5,14M
AGHAureus Greenway Holdings Inc	US$ 3,59 (-33,40%)	987,24k
BOXLBoxlight Corporation	US$ 2,12 (-31,61%)	525,94k
NVDANVIDIA Corporation	US$ 130,28 (-3,09%)	246,72M
PLTRPalantir Technologies Inc	US$ 90,68 (-10,53%)	180,51M
YYAIConnexa Sports Technologies Inc	US$ 1,245 (94,50%)	150,24M
STECSantech Holdings Limited	US$ 1,575 (142,20%)	121,33M
ADTXAditxt Inc	US$ 0,0867 (-5,25%)	118,7M

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

PMGC Holdings Inc (ELAB) Cours

PMGC Holdings Inc (ELAB)

Votre Hub pour des idées et discussions en direct en temps réel

Statistiques et détails clés

À propos de PMGC Holdings Inc

ELAB Dernières nouvelles

Form PRE 14A - Other preliminary proxy statements

Form 8-K - Current report

Northstrive Biosciences Inc., a Subsidiary of PMGC Holdings Inc., Announces Successful Submission of Pre-IND Meeting Request to FDA for EL-22, a Potential Breakthrough Obesity Therapy Targeting Fat Loss and Muscle Preservation in Combination with GLP-1 Rec

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form EFFECT - Notice of Effectiveness

Form 8-K - Current report

Northstrive Biosciences, Inc., a Subsidiary of PMGC Holdings Inc., Reports Positive Updates for Obesity Drug Candidates Targeting Fat Loss and Muscle Preservation used in Combination with GLP-1

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors

PMGC Capital LLC, a subsidiary of PMGC Holdings Inc., Begins to Build Portfolio with Strategic Acquisition of shares in U.S.-Focused Uranium Energy and Fire Prevention Technology Companies

Northstrive Biosciences Inc., a Subsidiary of PMGC Holdings Inc., Signs Agreement For Preclinical Mouse Study of EL-32, a Potential Breakthrough Obesity Therapy Targeting Fat Loss and Muscle Preservation in Combination with GLP-1

Form PRE 14A - Other preliminary proxy statements

Form 8-K - Current report

Northstrive Biosciences Inc., a Subsidiary of PMGC Holdings Inc., Announces Successful Submission of Pre-IND Meeting Request to FDA for EL-22, a Potential Breakthrough Obesity Therapy Targeting Fat Loss and Muscle Preservation in Combination with GLP-1 Rec

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form EFFECT - Notice of Effectiveness

Form 8-K - Current report

Northstrive Biosciences, Inc., a Subsidiary of PMGC Holdings Inc., Reports Positive Updates for Obesity Drug Candidates Targeting Fat Loss and Muscle Preservation used in Combination with GLP-1

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors

PMGC Capital LLC, a subsidiary of PMGC Holdings Inc., Begins to Build Portfolio with Strategic Acquisition of shares in U.S.-Focused Uranium Energy and Fire Prevention Technology Companies

Northstrive Biosciences Inc., a Subsidiary of PMGC Holdings Inc., Signs Agreement For Preclinical Mouse Study of EL-32, a Potential Breakthrough Obesity Therapy Targeting Fat Loss and Muscle Preservation in Combination with GLP-1

Form 8-K - Current report

Form 8-K - Current report

ELAB - Frequently Asked Questions (FAQ)

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Supprimer les publicités